Author + information
- Received August 14, 2017
- Revision received November 16, 2017
- Accepted November 27, 2017
- Published online February 5, 2018.
- Elizabeth Potter, MBBS and
- Thomas H. Marwick, MBBS, PhD, MPH∗ ()
- ↵∗Address for correspondence:
Dr. Thomas H. Marwick, Baker Heart and Diabetes Institute, Melbourne, P.O. Box 6492, Melbourne, Victoria 3004, Australia.
Left ventricular (LV) ejection fraction (LVEF) is a simple measure of global systolic function that pervades the risk evaluation and management of many cardiovascular diseases. However, this parameter is limited not only by technical challenges, but also by pathophysiological entities where the ratio of stroke volume to LV cavity size is preserved. The assessment of global longitudinal strain (GLS) from speckle-tracking analysis of 2-dimensional echocardiography has become a clinically feasible alternative to LVEF for the measurement of myocardial function. Evidence gathered over the last decade has shown GLS to be more sensitive to left ventricular dysfunction (LVD) than LVEF and to provide additional prognostic information. The technology is validated, reproducible within an acceptable range, and widely available. GLS has been proposed as the test of choice in guidelines for monitoring of asymptomatic cardiotoxicity related to chemotherapy. It also has the potential to improve risk stratification, redefine criteria for disease classification, and determine treatment in asymptomatic LVD resulting from a variety of etiologies. GLS provides utility across the spectrum of heart failure (and LVEF) as well as in the evaluation of valvular heart disease. There is a strong case for incorporation of GLS into clinical decision making. This review appraises the evidence addressing the utility of GLS as a complementary metric to LVEF for incorporation into mainstream clinical practice.
- global longitudinal strain
- heart failure
- left ventricular dysfunction
- left ventricular ejection fraction
Dr. Marwick has received research support from GE Medical Systems for an ongoing research study on the use of strain for the assessment of cardiotoxicity. Dr. Potter is supported by research scholarships from Monash University and the Baker Heart and Diabetes Institute.
- Received August 14, 2017.
- Revision received November 16, 2017.
- Accepted November 27, 2017.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.